Paliperidone Extended Release
Tóm tắt
Paliperidone, the major active metabolite of the atypical antipsychotic risperidone, is available in an oral extended-release (ER) formulation (Invega®) and is indicated for the acute and maintenance treatment of schizophrenia in adults in the US and the EU. Once-daily paliperidone ER provides stable plasma drug concentrations over a 24-hour period and may be initiated at therapeutically effective dosages without the need for titration. Paliperidone ER 3–12 mg/day improved Positive and Negative Syndrome Scale (PANSS) total scores (primary endpoint) from baseline to study end to a significantly greater extent than placebo in 6-week, double-blind trials in patients with acute symptoms of schizophrenia. The significant improvement in PANSS total score was seen after 4 days of treatment in some trials and paliperidone ER was effective against both positive and negative symptoms of the disease. End of treatment clinical response rates were significantly higher in paliperidone ER recipients than in those who received placebo. The efficacy of paliperidone ER was maintained with longer-term treatment (up to 52 weeks) in open-label extensions of placebo-controlled trials. When compared with quetiapine, paliperidone ER was associated with significantly greater improvements in PANSS total scores from baseline at 2 weeks (primary endpoint) in patients with acute schizophrenia, and at 6 weeks. The two drugs did not significantly differ in terms of clinical response rates. In the only trial to evaluate paliperidone ER for the prevention of symptom recurrence, paliperidone ER recipients had a significantly longer time to recurrence than did placebo recipients, as well as significantly less deterioration of symptom severity. In a 6-month, open-label trial in patients with non-acute schizophrenia, PANSS total scores, PANSS subscale scores and all five Marder factor scores did not significantly differ between paliperidone ER and olanzapine, but were significantly reduced from baseline at endpoint in both treatment groups. In adults with non-acute schizophrenia who were previously unsuccessfully treated with other oral antipsychotics and switched to paliperidone ER, PANSS total scores, PANSS subscale scores and all five Marder factor scores were significantly decreased from baseline at week 26 or endpoint. Paliperidone ER was generally well tolerated during short- and longer-term use and had a tolerability profile generally similar to that of its parent drug, risperidone. There were no unexpected tolerability findings during treatment of up to 52 weeks in duration. Paliperidone ER appeared to have little pro-arrhythmic potential and little effect on plasma glucose, lipid or insulin levels, but increased plasma prolactin levels over both short- and longer-term treatment periods. Clinically significant gains in bodyweight were seen in 15% of patients treated with paliperidone ER during the extension phase of placebo-controlled trials. Pooled analyses revealed that extrapyramidal symptoms occurred in approximately a quarter of the patients treated with higher doses of paliperidone ER (9 and 12 mg/day) in 6-week trials, and in 25% of paliperidone ER (mean dosage 10 mg/day) recipients during the 52-week extension phases. Although additional active comparator trials would be of interest, paliperidone ER is a useful option in the treatment and prevention of the acute symptoms of schizophrenia and may also be of use in patients with non-acute disease, including those previously unsuccessfully treated with other oral antipsychotics.
Tài liệu tham khảo
National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). National clinical guideline number 82 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdf [Accessed 2010 Jun 8]
Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 Feb; 161 (2 Suppl.): 1–56
Masand PS, Roca M, Turner MS, et al. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009; 11(4): 147–54
Marchese G, Pittau B, Casu G, et al. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. Eur Psych 2010; 25(2): 92–100
Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs 2010; 24(2): 92–100
Ortho-McNeil-Janssen Pharmaceuticals. Invega® (paliperidone) extended-release tablets: US prescribing information [online]. Available from URL: http://www.invega.com/invega/shared/pi/invega.pdf#zoom=100 [Accessed 2010 May 24]
European Medicines Agency. Invega (paliperidone prolongedrelease tablets): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/invega/invega.htm [Accessed 2009 Nov 30]
Yang LP, Plosker GL. Paliperidone extended release. CNS Drugs 2007; 21(5): 417–25; discussion 426-7
Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies [abstract no. PIII-57]. Clin Pharmacol Ther 2006 Feb; 79(2): P74
Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008 Apr; 197(2): 229–35
Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005 May; 162(5): 1010–2
Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol. Epub 2009 Oct 13
Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007 Feb; 90(1): 147–61
Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007 Jul; 93(1–3): 117–30
Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007 Dec 15; 62(12): 1363–70
Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebocontrolled study with six-month open-label extension. Am J Geriatr Psychiatry 2008 Jan; 16(1): 31–43
Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009 Jun; 166(6): 691–701
Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008 May; 69(5): 817–29
Kramer M, Eerdekens M, Lane R, et al. Metabolic outcomes, in terms of weight, glucose and lipid profiles, in patients with schizophrenia treated with paliperidone extended-release tablets for 52 weeks [abstract]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19–24; San Diego (CA), 213-4
Eerdekens M, Kramer M, Cleton A, et al. Paliperidone extended-release and quetiapine therapy in schizophrenia or schizoaffective disorder: evaluation of QT/QTc intervals. Eur Neuropsychopharmacol 2007 Oct; 17 Suppl. 4: 469
Schreiner A, Korcsog P, Niehaus D, et al. A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia [abstract no. SCH-3020]. 15th Biennial Winter Workshop on Psychoses; 2009 Nov 15–18; Barcelona
Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007 Sep; 22(5): 299–308
European Medicines Agency. Invega (paliperidone prolonged-release tablets): scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/invega/H-746-en6.pdf [Accessed 2009 Nov 30]
Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for longacting injectable risperidone. Am J Psychiatry 2006 Mar; 163(3): 396–401
Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157(4): 514–20
Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy or clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999 Feb; 156(2): 286–93
Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008 Nov; 23(6): 343–56
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
Vermeir M, Boom S, Naessens I, et al. Absorption, metabolism and excretion of a single oral dose of (14)C-paliperidone 1 mg in healthy subjects [abstract no. P.8.097]. Eur Neuropsychopharmacol 2005 Oct; 15 Suppl. 3: 648–649. Plus poster presented at the 18th European College of Neuropsychopharmacology Congress; 2005 Oct 22–26; Amsterdam
Cleton A, Rossenu S, Vermeulen A, et al. A pharmacokinetic model to document the interconversion between paliperidone’s enantiomers [abstract no. PII-72]. Clin Pharmacol Ther 2006 Feb 1; 79(2): 55
Rossenu S, Crauwels H, Cleton A, et al. Evaluation of the pharmacokinetics of several formulations of paliperidone. AAPS J 2006; 8 Suppl. 2: 1042
Cirincione BB, Redman ML, Fiedler-Kelly J, et al. Population pharmacokinetics of paliperidone ER in healthy and schizophrenia patients. Clin Pharmacol Ther 2007 Mar; 81 Suppl. 1: 19
Boom S, Talluri K, Janssens L, et al. Single- and multipledose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009 Nov; 49(11): 1318–30
Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine on the pharmacokinetics of paliperidone extendedrelease tablets. Pharmacopsychiatry 2009 Jul; 42(4): 158–63
Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol 2009; 24: 532–9
Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007 Feb; 27(1): 6–14
Canuso C, Carothers J, Dirks B, et al. A double-blind, placebo-controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia [abstract]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC, 166
Schreiner A, Tessier C, Hoeben D, et al. A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia [abstract]. 18th European Congress of Psychiatry; 2010 Feb 27–Mar 2; Munich
Schreiner A, Hoeben D, Lahaye M, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with other oral antipsychotics [abstract]. 18th European Congress of Psychiatry; 2010 Feb 27–Mar 2; Munich
Schreiner A, Hoeben D, Lahaye M, et al. Patient functioning with flexible doses of paliperidone ER: a 6-month prospective study [abstract]. 18th European Congress of Psychiatry; 2010 Feb 27–Mar 2; Munich
Schreiner A, Hoeben D, Lahaye M, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone [abstract]. 18th European Congress of Psychiatry; 2010 Feb 27–Mar 2; Munich
Howland RH. Paliperidone extended-release tablets: a new atypical antipsychotic. J Psychosoc Nurs Ment Health Serv 2007 May; 45(5): 15–8
Salimi K, Jarskog LF, Leiberman JA. Antipsychotic drugs for first-episode schizophrenia. CNS Drugs 2009; 23(10): 837–55
Mortimer A. How do we choose between atypical antipsychotics? The advantages of amisulpride. Int J Neuropsychopharmacol 2004; 7 Suppl. 1: S21–5
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004 Mar; 161(3): 414–25
Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001 Mar; 158(3): 360–9
Falkai P. Limitations of current therapies: why do patients switch therapies? Eur Neuropsychopharmacol 2008; 18 Suppl.: S135–9
American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27(2): 596–601
Jones A. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia. J Psychiatr Ment Health Nurs 2008 Dec; 15(10): 792–9
Hough D, Nuamah IF, Lim P, et al. Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis [letter]. J Clin Psychopharmacol 2009 Oct; 29(5): 496–7
Schreiner A, Badescu GM, Jukic V, et al. Safety, tolerability and treatment response of flexible doses of paliperidone ER in acutely exacerbated patients with schizophrenia [abstract]. 9th World Congress of the World Federation of Societies of Biological Psychiatry; 2009 Jun 28–Jul 2; Paris
Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evidence 2008; 2(4): 261–71
Nussbaum A, Stroup TS. Oral paliperidone for schizophrenia. Cochrane Database Syst Rev 2009; (2): CD006369
US National Institutes of Health. A double-blind, placebocontrolled study of the safety and efficacy of paliperidone extended release (ER) in the treatment of schizophrenia in adolescent patients [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/record/NCT00518323 [Accessed 2010 May 3]
Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008; 7: 16
Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral typical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008 Dec; 24(12): 3341–55
Berto P, Negrini C, Ferrannini L. Analisi costo-efficacia di paliperidone ER nel trattamento delle ricadute della schizofrenia, nella prospettiva del Sistema Sanitario Nazionale italiano. Farmeconomia e Percorsi Terapeutici 2008; 9(2): 95–108